Table 1.
Clinicopathological characteristics of the patient cohort (n = 11) before ALPPS
| Variable | Rescue ALPPS (n = 11) |
|---|---|
| Median age, years (range) | 67 (41–74) |
| Male/female gender | 8/3 |
| Median BMI (range) | 26.1 (22.2–29.4) |
| ASA-class 1–2 | 9 |
| ASA-class 3 | 2 |
| Synchronous/metachronous metastases | 6/5 |
| Median number of liver metastases (range) | 7 (2–20) |
| Tumor localization | |
| Right lobe + segment 4 | 7 |
| Right lobe + segment 4 + left lateral segment | 4 |
| Chemotherapy before ALPPS | |
| Oxaliplatin based | 7 |
| Irinotecan based | 4 |
| Targeted therapy | 5 |
| Number of chemotherapy cycles (range) | 7 (4–14) |
| Days between chemo and ALPPS (range) | 85 (26–172) |
| Portal vein occlusion prior to ALPPS | |
| Portal vein embolization (PVE) | 5 |
| Portal vein ligation (PVL) | 4 |
| First PVL then PVE | 2 |
| TELV, ml (range) | 1651 (1436–2070) |
| FLR before PVO, ml (range) | 250 (180–370) |
| FLR/BW ratio before PVO, % (range) | 0.33 (0.25–0.40) |
| sFLR before PVO, % (range) | 14.9 (11.9–19.7) |
| Growth of FLR after PVO, % (range) | 26.8 (−7.3–66.7) |
| Days from PVO to CT | 28 (19–33) |
| FLR before ALPPS, ml (range) | 312 (260–450) |
| FLR/BW ratio before ALPPS, % (range) | 0.41 (0.35–0.49) |
| sFLR before ALPPS, % (range) | 18.7 (16.1–23.8) |
ASA American Society of Anesthesiologists Physical Classification System, TELV total estimated liver volume, FLR future liver remnant, sFLR standardized FLR, FLR/BW ratio FLR to body weight ratio